[PDF] Top 20 Proyecto interdisciplinar para el aprendizaje de la estimación a través de la Educación Física.

... and meta-analysis is reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement and was registered at International Prospective Register of ... See full document

... The meta-analysis aimed to compare the efficacy and safety of erlotinib versus ...in advanced non-small cell lung cancer ...and chemotherapy were ... See full document

... breast cancer, renal cell carcinoma, gastric cancer, colorectal cancer and leukemia [12, ...improve patients’ cellular immune function in NSCLC [18, 19]. A meta-analysis ... See full document

... of patients showing a complete response or partial response during the ...110 patients were to be recruited to obtain 100 evalu- able patients (50 in each study group), considering a dropout rate of ... See full document

... a meta-analysis of randomised trials investigating the value of adding chemotherapy to primary treatment for non-small cell lung cancer (NSCLC) suggested a ... See full document

... anlotinib versus chemotherapy only for refractory NSCLC ...in advanced NSCLC as a second- or third-line ...anlotinib plus chemotherapy arm, the ORR and DCR were 27% and 78%, ... See full document

... adjuvant chemotherapy arm in stage IB or II pa- ...the chemotherapy arm and that this survival rate was maintained at 7 years ...IIIA patients. A meta-analysis based on collected and ... See full document

... NSCLC Meta-analysis Collaborative Group [54] showed a benefit of adjuvant chemotherapy after surgery from the results that the meta-analysis of surgery plus chemotherapy ... See full document

... in patients with PD-L1 TPS of 1–49% (HR, ...because patients with high PD-L1 expression repre- sent a minority of those with NSCLC ...of patients with advanced NSCLC ever receive second-line ... See full document

... their patients, and the very ill patients that want to get better at all ...of cetuximab, over- whelming evidence, particularly in meta-analysis studies, has shown that patients ... See full document

... of advanced lung ...PBDC versus PBDC alone for treating advanced ...Endostar plus PBDC in ORR was found (OR = ...A meta- analysis of DCR was also conducted (OR = ... See full document

... ing patients aged 18 or older, with advanced NSCLC previ- ously treated with 1 or 2 previous regimens and refractory (progressive disease within 90 days from the last treatment dose) or intolerant to the ... See full document

... of patients in the placebo arms went on to receive the trial agent on ...control patients who may have deteriorated rapidly and been ineligible to receive the second-line ...in patients who have had ... See full document

... There is strong body of evidence from both preclinical and clinical studies that specific biomarkers can potentially predict response to a particular type of chemotherapy, but no such biomarkers have been used so ... See full document

... both gefitinib and docetaxel groups (median survival ...mutant patients was not statistically significant (HR ...in patients with wild-type EGFR, the response rate was higher in the docetaxel arm ... See full document

... be moving toward developing a personalized prescription for cancer treatment. New developments in the use of immune- checkpoint inhibitors and immunotherapy will be seen in the coming years. Further research is ... See full document

... We have a much better understanding of some of the driver mutations that impact patient outcome in lung cancer. In the com- ing years our ability to target pathways of interest as opposed to individual ... See full document

... in patients treated with pembrolizumab plus carboplatin and pemetrexed (55%; 95%CI: 42 – 68) com- pared to chemotherapy alone (29%; 95%CI: 18 – ...to chemotherapy alone (HR: ...with ... See full document

... Two reviewers (Yuan-Yuan Chen and Lin-Wei Wang) inde- pendently extracted the following data from each enrolled trial: publication year, first author, pathologic stage, median follow-up time, treatment compliance, number ... See full document

... to chemotherapy (docetaxel) as second-line therapy for advanced NSCLC with wild-type ...registered patients, 540 were genotyped and 222 were ...to gefitinib in wild-type EGFR nonsquamous NSCLC ... See full document